218 related articles for article (PubMed ID: 27729425)
21. Copeptin in patients with acute myocardial infarction and newly detected glucose abnormalities - A marker of increased stress susceptibility? A report from the Glucose in Acute Myocardial Infarction cohort.
Smaradottir MI; Ritsinger V; Gyberg V; Norhammar A; Näsman P; Mellbin LG
Diab Vasc Dis Res; 2017 Mar; 14(2):69-76. PubMed ID: 28118730
[TBL] [Abstract][Full Text] [Related]
22. Increased plasma concentrations of midregional proatrial natriuretic Peptide is associated with risk of cardiorenal dysfunction in type 1 diabetes.
Theilade S; Hansen TW; Goetze JP; Rossing P
Am J Hypertens; 2015 Jun; 28(6):772-9. PubMed ID: 25468806
[TBL] [Abstract][Full Text] [Related]
23. Copeptin is an independent predictor of diabetic heart disease and death.
Enhörning S; Hedblad B; Nilsson PM; Engström G; Melander O
Am Heart J; 2015 Apr; 169(4):549-56.e1. PubMed ID: 25819862
[TBL] [Abstract][Full Text] [Related]
24. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians.
Pavkov ME; Bennett PH; Knowler WC; Krakoff J; Sievers ML; Nelson RG
JAMA; 2006 Jul; 296(4):421-6. PubMed ID: 16868300
[TBL] [Abstract][Full Text] [Related]
25. Variations in Risk of End-Stage Renal Disease and Risk of Mortality in an International Study of Patients With Type 1 Diabetes and Advanced Nephropathy.
Skupien J; Smiles AM; Valo E; Ahluwalia TS; Gyorgy B; Sandholm N; Croall S; Lajer M; McDonnell K; Forsblom C; Harjutsalo V; Marre M; Galecki AT; Tregouet DA; Wu CY; Mychaleckyj JC; Nickerson H; Pragnell M; Rich SS; Pezzolesi MG; Hadjadj S; Rossing P; Groop PH; Krolewski AS
Diabetes Care; 2019 Jan; 42(1):93-101. PubMed ID: 30455333
[TBL] [Abstract][Full Text] [Related]
26. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).
Schutte E; Lambers Heerspink HJ; Lutgers HL; Bakker SJ; Vart P; Wolffenbuttel BH; Umanath K; Lewis JB; de Zeeuw D; Gansevoort RT
Am J Kidney Dis; 2015 Sep; 66(3):450-8. PubMed ID: 25987260
[TBL] [Abstract][Full Text] [Related]
27. Relationship between ABO blood groups and cardiovascular disease in type 1 diabetes according to diabetic nephropathy status.
Parente EB; Harjutsalo V; Lehto M; Forsblom C; Sandholm N; Groop PH;
Cardiovasc Diabetol; 2020 May; 19(1):68. PubMed ID: 32429911
[TBL] [Abstract][Full Text] [Related]
28. Allelic variations in the CYBA gene of NADPH oxidase and risk of kidney complications in patients with type 1 diabetes.
Patente TA; Mohammedi K; Bellili-Muñoz N; Driss F; Sanchez M; Fumeron F; Roussel R; Hadjadj S; Corrêa-Giannella ML; Marre M; Velho G
Free Radic Biol Med; 2015 Sep; 86():16-24. PubMed ID: 25862415
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of placental growth factor and soluble Fms-like tyrosine kinase 1 as predictors of all-cause and cardiovascular mortality in patients with Type 1 diabetes with and without diabetic nephropathy.
Theilade S; Lajer M; Jorsal A; Tarnow L; Parving HH; Rossing P
Diabet Med; 2012 Mar; 29(3):337-44. PubMed ID: 21988672
[TBL] [Abstract][Full Text] [Related]
30. High levels of circulating TNFR1 increase the risk of all-cause mortality and progression of renal disease in type 2 diabetic nephropathy.
Fernández-Juárez G; Villacorta Perez J; Luño Fernández JL; Martinez-Martinez E; Cachofeiro V; Barrio Lucia V; Tato Ribera AM; Mendez Abreu A; Cordon A; Oliva Dominguez JA; Praga Terente M
Nephrology (Carlton); 2017 May; 22(5):354-360. PubMed ID: 27003829
[TBL] [Abstract][Full Text] [Related]
31. A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus.
Alkhalaf A; Bakker SJ; Bilo HJ; Gans RO; Navis GJ; Postmus D; Forsblom C; Groop PH; Vionnet N; Hadjadj S; Marre M; Parving HH; Rossing P; Tarnow L
Diabetologia; 2010 Dec; 53(12):2562-8. PubMed ID: 20711718
[TBL] [Abstract][Full Text] [Related]
32. Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.
Abbasi A; Corpeleijn E; Meijer E; Postmus D; Gansevoort RT; Gans RO; Struck J; Hillege HL; Stolk RP; Navis G; Bakker SJ
Diabetologia; 2012 Jul; 55(7):1963-70. PubMed ID: 22526609
[TBL] [Abstract][Full Text] [Related]
33. Death, end-stage renal disease and renal function decline in patients with diabetic nephropathy in French cohorts of type 1 and type 2 diabetes.
Hadjadj S; Cariou B; Fumeron F; Gand E; Charpentier G; Roussel R; Kasmi AA; Gautier JF; Mohammedi K; Gourdy P; Saulnier PJ; Feigerlova E; Marre M;
Diabetologia; 2016 Jan; 59(1):208-216. PubMed ID: 26486355
[TBL] [Abstract][Full Text] [Related]
34. Higher Collagen VI Formation Is Associated With All-Cause Mortality in Patients With Type 2 Diabetes and Microalbuminuria.
Rasmussen DGK; Hansen TW; von Scholten BJ; Nielsen SH; Reinhard H; Parving HH; Tepel M; Karsdal MA; Jacobsen PK; Genovese F; Rossing P
Diabetes Care; 2018 Jul; 41(7):1493-1500. PubMed ID: 29643059
[TBL] [Abstract][Full Text] [Related]
35. Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study.
Garofolo M; Gualdani E; Giannarelli R; Aragona M; Campi F; Lucchesi D; Daniele G; Miccoli R; Francesconi P; Del Prato S; Penno G
Cardiovasc Diabetol; 2019 Nov; 18(1):159. PubMed ID: 31733651
[TBL] [Abstract][Full Text] [Related]
36. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study.
Khan SQ; Dhillon OS; O'Brien RJ; Struck J; Quinn PA; Morgenthaler NG; Squire IB; Davies JE; Bergmann A; Ng LL
Circulation; 2007 Apr; 115(16):2103-10. PubMed ID: 17420344
[TBL] [Abstract][Full Text] [Related]
37. Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes.
Winther SA; Øllgaard JC; Tofte N; Tarnow L; Wang Z; Ahluwalia TS; Jorsal A; Theilade S; Parving HH; Hansen TW; Hazen SL; Pedersen O; Rossing P
Diabetes Care; 2019 Aug; 42(8):1512-1520. PubMed ID: 31123156
[TBL] [Abstract][Full Text] [Related]
38. Copeptin and insulin-like growth factor binding protein-1 during follow-up after an acute myocardial infarction in patients with type 2 diabetes: A report from the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction 2 cohort.
Smáradóttir MI; Catrina SB; Brismar K; Norhammar A; Gyberg V; Mellbin LG
Diab Vasc Dis Res; 2019 Jan; 16(1):22-27. PubMed ID: 30309264
[TBL] [Abstract][Full Text] [Related]
39. Cumulative Kidney Complication Risk by 50 Years of Type 1 Diabetes: The Effects of Sex, Age, and Calendar Year at Onset.
Costacou T; Orchard TJ
Diabetes Care; 2018 Mar; 41(3):426-433. PubMed ID: 28931542
[TBL] [Abstract][Full Text] [Related]
40. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.
Lajer M; Tarnow L; Jorsal A; Teerlink T; Parving HH; Rossing P
Diabetes Care; 2008 Apr; 31(4):747-52. PubMed ID: 18162497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
